CAR T-Cell Therapy Shows Promise Beyond Cancer in Treating Lupus
核心洞察
Early results indicate CAR T-cell therapy may be effective in treating autoimmune diseases like lupus (搜索) by targeting B cells (搜索).
Researchers are optimistic about CAR T therapies' potential beyond cancer, with lupus (搜索) being a prime target due to its B-cell-driven nature.
The therapy involves engineering a patient's own T cells to target and kill specific cell types, offering a personalized treatment approach.
CAR T-cell therapy, initially developed to combat blood cancers, is showing promising early results in treating the autoimmune disease lupus (搜索). Researchers, including Penn Medicine (搜索) CAR T pioneer Carl June, are encouraged by these findings, suggesting the potential for broader applications of this personalized immunotherapy.
T cells, critical components of the immune system, are engineered in CAR T-cell therapy to target and eliminate specific cell types. This approach involves collecting a patient's T cells, modifying them in the lab, and reinfusing them back into the patient as a "living drug."
The first CAR T therapy, Kymriah, was developed by June and his team at Penn Medicine (搜索) and received FDA approval in 2017. Currently, there are six FDA-approved CAR T-cell therapies in the United States, each targeting different cancers. Given the success in cancer treatment, researchers are now exploring the potential of CAR T-cell therapy for other conditions, particularly those driven by B cells (搜索), such as lupus (搜索). In lupus, B cells produce antibodies that attack the body's own organs and tissues.
Lupus (搜索) is considered an obvious choice for CAR T-cell therapy because it is driven by B cells (搜索). Experimental CAR T therapies against lupus can employ existing anti-B-cell designs. Dozens of research teams around the world, including teams at Penn Medicine (搜索) and biotech spinoffs who are working to develop effective treatments from Penn-developed personalized cellular therapy constructs, are examining these potential new applications.